Letter to the editor—chronic disseminated candidiasis
- 145 Downloads
We read with interest the report by Pepa and colleagues regarding the management of chronic disseminated candidiasis (CDC) in patients with hematologic malignancies . In their experience, only two of six patients (33%) with CDC responded to azole therapy, and only three (50%) received chemotherapy as planned, possibly having an adverse influence on the outcome of the underlying malignancy. In contrast, all six patients treated with high-dose liposomal amphotericin B (HD L-AmB) achieved complete resolution of CDC and only one had to interrupt the planned chemotherapy program. Patients receiving therapy with echinocandins also did not appear to do as well as those treated with HD L-AmB. Whilst the overall number of patients treated in this study was small and may have falsely exaggerated differences, this experience appears to be at odds with our clinical experience, as well as that of several other investigators who have reported response rates associated with azole therapy for CDC...
Compliance with ethical standards
Conflict of interest
The author declares that he has no conflict of interest.